amg0001
mAbexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 30, 2020 (NCT04267640)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Hepatocyte growth factorINHIBITOR
HGF inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- amg0001
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04267640 | Phase 2 | Jan 30, 2020 | AnGes, Inc., University of California, San Francisco, University of Southern California |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AnGes, Inc. | For profit | 1 | 1 | 1 | 2020 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Southern California | Academic/Hospital | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1